Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy
2006
Case of Midline Carcinoma with BRD4-NUT Fusion
Sample size: 1
publication
Evidence: low
Author Information
Author(s): Engleson Jens, Soller Maria, Panagopoulos Ioannis, Dahlén Anna, Dictor Michael, Jerkeman Mats
Primary Institution: Lund University Hospital
Conclusion
Docetaxel may be considered for initial chemotherapy in young patients with midline carcinoma showing specific genetic rearrangements.
Supporting Evidence
- The patient had a rapidly progressing tumor with a specific genetic rearrangement.
- Initial treatment with Ewing sarcoma chemotherapy was ineffective.
- Docetaxel and radiotherapy led to almost complete tumor disappearance.
Takeaway
A 30-year-old woman with a rare type of cancer responded well to a treatment with docetaxel and radiation, which made her tumor shrink almost completely.
Methodology
The study involved cytogenetic, FISH, and PCR analyses to diagnose the tumor and assess the treatment response.
Limitations
The study is based on a single case, limiting the generalizability of the findings.
Participant Demographics
One 30-year-old female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website